浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Research progress on clinical application of ruxolitinib
- ZHONGGUO YAOFANG Vol. 35, Issue 13, Pages: 1668-1672(2024)
- 作者机构：
海南医学院药学院，海口 571199
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.13.21
CLC： R961;R969Published：15 July 2024，
Received：02 November 2023，
Revised：20 June 2024，
- 稿件说明：
扫 描 看 全 文
冯世权,秦贞苗,胡雪等.鲁索替尼的临床应用研究进展 Δ[J].中国药房,2024,35(13):1668-1672.
FENG Shiquan,QIN Zhenmiao,HU Xue,et al.Research progress on clinical application of ruxolitinib[J].ZHONGGUO YAOFANG,2024,35(13):1668-1672.
冯世权,秦贞苗,胡雪等.鲁索替尼的临床应用研究进展 Δ[J].中国药房,2024,35(13):1668-1672. DOI： 10.6039/j.issn.1001-0408.2024.13.21.
FENG Shiquan,QIN Zhenmiao,HU Xue,et al.Research progress on clinical application of ruxolitinib[J].ZHONGGUO YAOFANG,2024,35(13):1668-1672. DOI： 10.6039/j.issn.1001-0408.2024.13.21.
摘要
鲁索替尼是一种选择性靶向Janus激酶（JAK）的小分子抑制剂，可在JAK1、JAK2结构域与催化位点上的三磷酸腺苷竞争性结合，从而抑制JAK活化和信号转导及转录激活蛋白（STAT）磷酸化，阻止JAK-STAT信号通路的表达。口服鲁索替尼对骨髓纤维化和真性红细胞增多症展现出良好的疗效。外用的鲁索替尼乳膏是美国FDA批准的首个非节段型白癜风家庭治疗药物，目前虽尚未在我国上市，但已于2023年8月落地国内医疗先行区，有望成为白癜风治疗的新突破。鲁索替尼乳膏还被多项临床案例证明对特应性皮炎、斑秃等具有显著疗效，具有较大的应用前景。
Abstract
Ruxolitinib， a small molecule inhibitor， selectively targets Janus kinase （JAK） by competitively binding to adenosine triphosphate on the catalytic site of the JAK1 and JAK2 domain， thereby inhibiting JAK activation and signal transducer and activator of transcription （STAT） phosphorylation and prevents the expressions of the JAK-STAT signaling pathway. Oral ruxolitinib has demonstrated promising efficacy for myelofibrosis and polycythemia vera. The topical Ruxolitinib cream， approved by the US FDA as the first non-segmental vitiligo home treatment drug， is set to be launched in domestic medical pioneer areas in August 2023 and is expected to bring about a breakthrough in the treatment of vitiligo. Clinical cases have also shown that Ruxolitinib cream has significant curative effects on atopic dermatitis， alopecia areata， and other conditions， indicating great application prospects.
关键词
鲁索替尼JAK-STAT信号通路JAK抑制剂骨髓纤维化真性红细胞增多症白癜风皮肤病
Keywords
JAK-STAT signaling pathwayJAK inhibitorsmyelofibrosispolycythemia veravitiligoskin diseases
references
XUE C，YAO Q F，GU X Y，et al. Evolving cognition of the JAK-STAT signaling pathway：autoimmune disorders and cancer[J]. Signal Transduct Target Ther，2023，8（1）：204.
SHAWKY A M，ALMALKI F A，ABDALLA A N，et al. A comprehensive overview of globally approved JAK inhibitors[J]. Pharmaceutics，2022，14（5）：1001.
LIU J，WANG F P，LUO F M. The role of JAK/STAT pathway in fibrotic diseases：molecular and cellular mechanisms[J]. Biomolecules，2023，13（1）：119.
SMITH P，YAO W Q，SHEPARD S，et al. Developing a JAK inhibitor for targeted local delivery：ruxolitinib cream[J]. Pharmaceutics，2021，13（7）：1044.
GANGAT N，TEFFERI A. Myelofibrosis biology and contemporary management[J]. Br J Haematol，2020，191（2）：152-170.
HARRISON C，KILADJIAN J J，AL-ALI H K，et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis[J]. N Engl J Med，2012，366（9）：787-798.
CLAUDIANI S，MASON C C，MILOJKOVIC D，et al. Carfilzomib enhances the suppressive effect of ruxolitinib in myelofibrosis[J]. Cancers （Basel），2021，13（19）：4863.
LOSCOCCO F，VISANI G，GALIMBERTI S，et al. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia[J]. Front Oncol，2019，9：939.
SAHA C D，HARRISON C. Fedratinib，the first selective JAK2 inhibitor approved for treatment of myelofibrosis：an option beyond ruxolitinib[J]. Expert Rev Hematol，2022，15（7）：583-595.
CERVANTES F，ROSS D M，RADINOFF A，et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia：the REALISE phase 2 study[J]. Leukemia，2021，35（12）：3455-3465.
YANG Y F，LUO H M，ZHENG Y H，et al. Low-dose ruxolitinib shows effective in treating myelofibrosis[J]. Ann Hematol，2021，100（1）：135-141.
MOYO T K，KISHTAGARI A，VILLAUME M T，et al. PI3K inhibition restores and amplifies response to ruxolitinib in patients with myelofibrosis[J]. Clin Cancer Res，2023，29（13）：2375-2384.
KUYKENDALL A T. Treatment of hydroxyurea-resistant/intolerant polycythemia vera：a discussion of best practices[J]. Ann Hematol，2023，102（5）：985-993.
BEWERSDORF J P，HOW J，MASAROVA L，et al. Moving toward disease modification in polycythemia vera[J]. Blood，2023，142（22）：1859-1870.
VERSTOVSEK S，PASSAMONTI F，RAMBALDI A， et al. A phase 2 study of ruxolitinib，an oral JAK1 and JAK2 inhibitor，in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea[J]. Cancer，2014，120（4）：513-520.
VANNUCCHI A M，KILADJIAN J J，GRIESSHAMMER M，et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera[J]. N Engl J Med，2015，372（5）：426-435.
XU C，LEI Z X，WANG L，et al. The effect of transplantation of cultured autologous melanocytes on CXCL9，CXCL10 and CXCL11 expressions in vitiligo[J]. Indian J Dermatol，2023，68（4）：486.
KUBELIS-LÓPEZ D E，ZAPATA-SALAZAR N A，SAID-FERNÁNDEZ S L，et al. Updates and new medical treatments for vitiligo （review）[J]. Exp Ther Med，2021，22（2）：797.
WU J，SMOGORZEWSKI J. Off-label studies on ruxolitinib in dermatology：a review[J]. J Dermatolog Treat，2022，33（2）：606-612.
SHEIKH A，RAFIQUE W，OWAIS R，et al. FDA approves ruxolitinib （Opzelura） for vitiligo therapy：a breakthrough in the field of dermatology[J]. Ann Med Surg，2022，81：104499.
ROTHSTEIN B，JOSHIPURA D，SARAIYA A，et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib[J]. J Am Acad Dermatol，2017，76（6）：1054-1060.e1.
KOHLI I，VEENSTRA J，HAMZAVI I. Vitiligo assessment methods：Vitiligo Area Scoring Index and Vitiligo European Task Force assessment[J]. Br J Dermatol，2015，172（2）：318-319.
ROSMARIN D，PANDYA A G，LEBWOHL M，et al. Ruxolitinib cream for treatment of vitiligo：a randomized，controlled，phase 2 trial[J]. Lancet，2020，396（10244）：110-120.
ROSMARIN D，PASSERON T，PANDYA A G，et al. Two phase 3，randomized，controlled trials of ruxolitinib cream for vitiligo[J]. N Engl J Med，2022，387（16）：1445-1455.
LAUGHTER M R，MAYMONE M B C，MASHAYEKHI S，et al. The global burden of atopic dermatitis：lessons from the global burden of disease study 1990-2017[J]. Br J Dermatol，2021，184（2）：304-309.
FREITAS E，GOODERHAM M，TORRES T. New topical therapies in development for atopic dermatitis[J]. Drugs，2022，82（8）：843-853.
OWJI S，CALDAS S A，UNGAR B. Management of atopic dermatitis：clinical utility of ruxolitinib[J]. J Asthma Allergy，2022，15：1527-1537.
BISSONNETTE R，CALL R S，RAOOF T，et al. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis[J]. Am J Clin Dermatol，2022，23（3）：355-364.
KIM B S，SUN K，PAPP K，et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis：results from a phase 2，randomized，dose-ranging，vehicle- and active-controlled study[J]. J Am Acad Dermatol，2020，82（6）：1305-1313.
KING B，KO J，FORMAN S，et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata：phase 2 results from a randomized controlled study[J]. J Am Acad Dermatol，2021，85（4）：847-853.
DAINICHI T，IWATA M，KAKU Y. Alopecia areata：what’s new in the diagnosis and treatment with JAK inhibitors?[J]. J Dermatol，2024，51（2）：196-209.
OLSEN E A，KORNACKI D，SUN K，et al. Ruxolitinib cream for the treatment of patients with alopecia areata：a 2-part，double-blind，randomized，vehicle-controlled phase 2 study[J]. J Am Acad Dermatol，2020，82（2）：412-419.
BAYART C B，DENIRO K L，BRICHTA L，et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata[J]. J Am Acad Dermatol，2017，77（1）：167-170.
ALMUTAIRI N，NOUR T M，HUSSAIN N H. Janus kinase inhibitors for the treatment of severe alopecia areata：an open-label comparative study[J]. Dermatology，2019，235（2）：130-136.
0
Views
1
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.